What are the alternate names for Actos (Pioglitazone) and Farsigia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alternate Names for Actos (Pioglitazone) and Farsigia

Actos is the brand name for pioglitazone hydrochloride, while there is no medication called "Farsigia" in the medical literature. 1, 2

Pioglitazone (Actos) Details

  • Pioglitazone is the generic name for the medication marketed under the brand name Actos by Takeda Pharmaceuticals 1, 3
  • Pioglitazone belongs to the thiazolidinedione (TZD) class of oral antidiabetic medications 2, 4
  • It is also known as a peroxisome proliferator-activated receptor γ (PPAR-γ) activator 2
  • The full chemical name is pioglitazone hydrochloride 3

Mechanism and Use

  • Pioglitazone improves insulin sensitivity in muscle and adipose tissue by activating the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma) 2, 4
  • It is indicated for the treatment of type 2 diabetes mellitus, either as monotherapy or in combination with sulfonylureas, metformin, or insulin 1
  • The medication is typically dosed at 15-45 mg once daily 4

Important Considerations

  • Pioglitazone has been associated with fluid retention and edema, which may exacerbate or lead to heart failure in predisposed individuals 1
  • The FDA has issued a Black Box Warning stating that thiazolidinediones, including pioglitazone, may cause or exacerbate heart failure 1
  • It should not be used in patients with NYHA class III or IV heart failure 1
  • Lower doses (15-30 mg) may help mitigate concerns about weight gain and edema 1

Regarding "Farsigia"

  • There is no medication with the name "Farsigia" mentioned in any of the provided medical literature or guidelines 1, 2
  • This may be a misspelling or confusion with another medication name
  • No alternative spelling variations of this name appear in the provided evidence

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pioglitazone Therapy for Type 2 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pioglitazone.

Drugs, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.